Skip to main content

Table 2 Change in lipid parameters observed with omega-3 carboxylic acids, omega-3 ethyl esters, and icosapent ethyl in patients with severe hypertriglyceridemia (triglyceride level ≥ 500 mg/dL)

From: The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia

 

OM3CA (Epanova) [17]

OM3EE (Lovaza) [14]

IPE (Vascepa) [16]

Parameter

Placebo (olive oil) (n = 100)

OM3CA 2 g/day (n = 100)

OM3CA 4 g/day (n = 99)

Placebo (corn oil) (n = 42)

OM3EE 4 g/day (n = 42)

Placebo (mineral oil) (n = 75)

IPE 4 g/day (n = 76)

TG

       

 Median BL, mg/dL

682

717

655

788

816

703

680

 Median percentage change from BL, %

−10

−25

−31

7

−45

10

−27

 Difference‡

–

−16**

−21***

–

−52

–

−33***

Non-HDL-C

       

 Median BL, mg/dL

215

205

225

292

271

229

225

 Median percentage change from BL, %

−1

−8

−8

−4

−14

8

−8

 Difference‡

–

−7*

−10**

–

−10

–

−18

HDL-C

       

 Median BL, mg/dL

29

27

29

24

22

27

27

 Median percentage change form BL, %

2

7

5

0

9

0

−4

 Difference‡

–

5†

4†

–

9

–

−4

Total cholesterol

       

 Median BL, mg/dL

246

241

254

314

296

256

254

 Median percentage change from BL, %

0

−6

−6

−2

−10

8

−7

 Difference‡

–

−6

−9

–

−8

–

−16

VLDL-C

       

 Median BL, mg/dL

125

123

126

175

175

124

123

 Median percentage change from BL, %

−11

−25

−35

−1

−42

14

−20

 Difference‡

–

−14

−21

–

−41

–

−29*

LDL-C

       

 Median BL, mg/dL

78

77

90

108

89

86

91

 Median percentage change from BL, %

10

21

26

−5

45

−3

−5

 Difference‡

–

13

15

–

49

–

−2

ApoB

       

 Median BL, mg/dL

110

114

118

ND

ND

118

121

 Median percentage change from BL, %

2

6

6

ND

ND

4

−4

 Difference‡

–

3

2

–

ND

–

−9*

  1. P-values from Wilcoxon rank sum test: *P < 0.05; **P < 0.01; ***P < 0.001; †not significant. Testing for statistical significance was performed for OM3CA (TG, non-HDL-C and HDL-C) and IPE (TG, VLDL-C, and ApoB) only. No statistical analysis was presented for OM3EE
  2. ‡Difference for OM3CA and IPE = median of [omega-3 fatty acid formulation % change – placebo % change] (Hodges-Lehmann Estimate); Difference for OM3EE = OM3EE median % change – placebo median % change
  3. The median placebo-corrected % change in lipid parameters reported for Omtryg, the generic form of Lovaza, are as follows: TG = −12 %, non-HDL-C = −9 %, HDL-C = 4 %, TC = −7 %, VLDL-C = −29 %, and LDL-C = 25 % [15]
  4. ApoB apolipoprotein B, BL baseline, HDL-C high-density lipoprotein cholesterol, IPE icosapent ethyl, LDL-C low-density lipoprotein cholesterol, ND not described, OM3CA omega-3 carboxylic acids, OM3EE omega-3 ethyl esters, TG triglyceride, VLDL-C very-low-density lipoprotein cholesterol